Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease

F Kronenberg1, H Kathrein, P König

  • 1Institute of Medical Biology and Human Genetics, Innsbruck, Austria.

Arteriosclerosis and Thrombosis : a Journal of Vascular Biology
|September 1, 1994
PubMed

Insights

In end-stage renal disease (ESRD) patients, the apolipoprotein(a) [apo(a)] phenotype, not just lipoprotein(a) [Lp(a)] levels, significantly predicts carotid atherosclerosis. This finding aids in assessing cardiovascular risk in dialysis patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Genetics

Background:

  • Atherosclerotic complications are a leading cause of death in hemodialysis patients.
  • High lipoprotein(a) [Lp(a)] plasma concentrations are an independent risk factor for atherosclerosis.
  • End-stage renal disease (ESRD) patients exhibit elevated Lp(a) levels, independent of apolipoprotein(a) [apo(a)] gene size variations.

Purpose of the Study:

  • To determine if Lp(a) concentrations and/or apo(a) phenotypes predict the severity of extracranial carotid artery atherosclerosis in ESRD patients.

Main Methods:

  • Studied 167 ESRD patients, assessing atherosclerotic plaques in carotid arteries.
  • Analyzed Lp(a) plasma concentrations and apo(a) phenotypes.
  • Utilized univariate and multivariate regression analyses to identify predictors of atherosclerosis.

Main Results:

  • 65% of patients had atherosclerotic plaques.
  • Patients with plaques were older and had more cardiovascular history.
  • Low-molecular-weight apo(a) isoforms (26.9% vs 8.5%) and higher mean Lp(a) levels (29.3 vs 19.7 mg/dL) were associated with plaques.
  • Lp(a) concentration correlated with the number of affected arterial sites.
  • Low-molecular-weight apo(a) phenotypes were linked to more affected arterial sites (3.62 vs 2.08).

Conclusions:

  • Age and apo(a) phenotype are significant predictors of carotid atherosclerosis in ESRD patients.
  • The apo(a) phenotype is a stronger predictor than Lp(a) concentration alone.
  • Apo(a) phenotype can help assess general atherosclerosis risk in ESRD patients.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...